NICE's cost-effectiveness range: should it be lowered?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS.PharmacoEconomics · 2022
   Article
2. Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations.PharmacoEconomics · 2020
   Review
3. Impact of a Global Pandemic on Health Technology Assessment.Applied health economics and health policy · 2020
   Article
4. Estimating Social Variation in the Health Effects of Changes in Health Care Expenditure.Medical decision making : an international journal of the Society for Medical Decision Making · 2020
   Article
5. The marginal benefits of healthcare spending in the Netherlands: Estimating cost-effectiveness thresholds using a translog production function.Health economics · 2019
   Article
6. Cognitive aids for people with early stage dementia versus treatment as usual (Dementia Early Stage Cognitive Aids New Trial (DESCANT)): study protocol for a randomised controlled trial.Trials · 2018
   Article
7. Cost-Effectiveness Thresholds: the Past, the Present and the Future.PharmacoEconomics · 2018
   Review
8. Improving the effectiveness of psychological interventions for depression and anxiety in the cardiac rehabilitation pathway using group-based metacognitive therapy (PATHWAY Group MCT): study protocol for a randomised controlled trial.Trials · 2018
   Article
9. Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.Frontiers in public health · 2018
   Review
10. Ethical Hurdles in the Prioritization of Oncology Care.Applied health economics and health policy · 2017
    Article
11. Should the Lambda (λ) Remain Silent?PharmacoEconomics · 2016
    Article
12. The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland's Health System?PharmacoEconomics · 2016
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as